Zura Bio provides clinical update on Phase 2 study of tibulizumab in hidradenitis suppurativa
ZURA•Zura Bio said its Phase 2 study of tibulizumab in hidradenitis suppurativa did not meet its primary or key secondary endpoints, and it will discontinue development of the drug for the condition. The company said the treatment was well tolerated and expects cash to fund operations through the end of 2028.
1. Study results
Zura Bio said its Phase 2 TIBUSHIELD study of tibulizumab (ZB-106) in hidradenitis suppurativa did not meet its primary endpoint or key secondary endpoints, including HiSCR50 and HiSCR75. The company is discontinuing development of tibulizumab for the condition. It said the drug was well tolerated, with safety consistent with IL-17 and BAFF inhibition profiles, and expects to have cash sufficient for operations through the end of 2028.
